BRPI0613999B8 - uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto - Google Patents

uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto

Info

Publication number
BRPI0613999B8
BRPI0613999B8 BRPI0613999A BRPI0613999A BRPI0613999B8 BR PI0613999 B8 BRPI0613999 B8 BR PI0613999B8 BR PI0613999 A BRPI0613999 A BR PI0613999A BR PI0613999 A BRPI0613999 A BR PI0613999A BR PI0613999 B8 BRPI0613999 B8 BR PI0613999B8
Authority
BR
Brazil
Prior art keywords
compound
combination
product
pharmaceutical composition
quinoline
Prior art date
Application number
BRPI0613999A
Other languages
English (en)
Portuguese (pt)
Inventor
Koul Anil
Francis Alain Lancois David
Emile Georges Guillemont Jérôme
Jozef Lodewijk Marcel Andries Koenraad
Madeleine Simone Motte Magali
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0613999(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0613999A2 publication Critical patent/BRPI0613999A2/pt
Publication of BRPI0613999B1 publication Critical patent/BRPI0613999B1/pt
Publication of BRPI0613999B8 publication Critical patent/BRPI0613999B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
BRPI0613999A 2005-06-28 2006-06-26 uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto BRPI0613999B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05105755.2 2005-06-28
EP05105755 2005-06-28
PCT/EP2006/063552 WO2007000434A1 (en) 2005-06-28 2006-06-26 Quinoline derivatives as antibacterial agents

Publications (3)

Publication Number Publication Date
BRPI0613999A2 BRPI0613999A2 (pt) 2011-03-01
BRPI0613999B1 BRPI0613999B1 (pt) 2020-04-22
BRPI0613999B8 true BRPI0613999B8 (pt) 2021-05-25

Family

ID=35447198

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613999A BRPI0613999B8 (pt) 2005-06-28 2006-06-26 uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto

Country Status (31)

Country Link
US (1) US20130030016A1 (enExample)
EP (1) EP1898909B1 (enExample)
JP (1) JP5193857B2 (enExample)
KR (1) KR101329587B1 (enExample)
CN (1) CN101252927B (enExample)
AP (1) AP2547A (enExample)
AR (1) AR054804A1 (enExample)
AU (1) AU2006263882B2 (enExample)
BR (1) BRPI0613999B8 (enExample)
CA (1) CA2612614C (enExample)
CY (1) CY1119402T1 (enExample)
DK (1) DK1898909T3 (enExample)
EA (1) EA014431B1 (enExample)
ES (1) ES2610472T3 (enExample)
HR (1) HRP20170044T1 (enExample)
HU (1) HUE030264T2 (enExample)
IL (1) IL188395A (enExample)
JO (1) JO3322B1 (enExample)
LT (1) LT1898909T (enExample)
MX (1) MX2008000079A (enExample)
MY (1) MY173664A (enExample)
NO (1) NO341285B1 (enExample)
NZ (1) NZ564340A (enExample)
PL (1) PL1898909T3 (enExample)
PT (1) PT1898909T (enExample)
RS (1) RS55601B1 (enExample)
SG (1) SG166798A1 (enExample)
TW (1) TWI413520B (enExample)
UA (1) UA88701C2 (enExample)
WO (1) WO2007000434A1 (enExample)
ZA (1) ZA200711148B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JP5397881B2 (ja) * 2008-09-04 2014-01-22 昇一 城武 グラム陽性細菌用抗菌剤及び抗菌活性増強剤
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
AU2018348796B2 (en) * 2017-10-13 2024-09-26 Adelaide university Zinc ionophores and uses thereof
CN110606825A (zh) * 2019-10-30 2019-12-24 成都海杰亚医药科技有限公司 一种制备吡啶-2-硫醇的方法
CN117843568A (zh) * 2024-01-03 2024-04-09 中国药科大学 一种芳烷基取代-1-甲基喹啉季铵盐类衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
AU2006263882B2 (en) 2012-12-13
EA014431B1 (ru) 2010-12-30
US20130030016A1 (en) 2013-01-31
IL188395A (en) 2012-05-31
JO3322B1 (ar) 2019-03-13
NO341285B1 (no) 2017-10-02
ZA200711148B (en) 2013-03-27
PL1898909T3 (pl) 2017-03-31
CA2612614A1 (en) 2007-01-04
WO2007000434A1 (en) 2007-01-04
IL188395A0 (en) 2008-08-07
EP1898909A1 (en) 2008-03-19
TW200800183A (en) 2008-01-01
CY1119402T1 (el) 2018-03-07
NO20080499L (no) 2008-02-29
CN101252927B (zh) 2014-01-01
EA200800151A1 (ru) 2008-06-30
BRPI0613999A2 (pt) 2011-03-01
TWI413520B (zh) 2013-11-01
UA88701C2 (ru) 2009-11-10
BRPI0613999B1 (pt) 2020-04-22
RS55601B1 (sr) 2017-06-30
MX2008000079A (es) 2008-03-19
MY173664A (en) 2020-02-14
EP1898909B1 (en) 2016-10-19
KR20080028459A (ko) 2008-03-31
KR101329587B1 (ko) 2013-11-15
DK1898909T3 (en) 2017-02-06
NZ564340A (en) 2011-02-25
PT1898909T (pt) 2016-12-07
AU2006263882A1 (en) 2007-01-04
AR054804A1 (es) 2007-07-18
AP2547A (en) 2012-12-26
CA2612614C (en) 2017-07-25
ES2610472T3 (es) 2017-04-27
CN101252927A (zh) 2008-08-27
JP2008546824A (ja) 2008-12-25
HK1120732A1 (en) 2009-04-09
LT1898909T (lt) 2017-02-10
JP5193857B2 (ja) 2013-05-08
HUE030264T2 (en) 2017-04-28
HRP20170044T1 (hr) 2017-03-10
SG166798A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
UY30759A1 (es) Compuestos quimicos
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
JOP20190142B1 (ar) مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2780 DE 16-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.